Los Angeles Capital Management LLC Sells 108,118 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Los Angeles Capital Management LLC decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 34.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 201,261 shares of the specialty pharmaceutical company's stock after selling 108,118 shares during the period. Los Angeles Capital Management LLC owned approximately 0.32% of Jazz Pharmaceuticals worth $24,236,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Centre Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $8,475,000. Newbridge Financial Services Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 254.5% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company's stock valued at $58,000 after purchasing an additional 336 shares during the period. HighPoint Advisor Group LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $240,000. Virtu Financial LLC increased its stake in Jazz Pharmaceuticals by 104.6% during the 4th quarter. Virtu Financial LLC now owns 8,877 shares of the specialty pharmaceutical company's stock worth $1,092,000 after buying an additional 4,538 shares during the period. Finally, V Square Quantitative Management LLC lifted its holdings in Jazz Pharmaceuticals by 63.9% in the 4th quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company's stock worth $84,000 after buying an additional 265 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the company's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Truist Financial restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Needham & Company LLC reissued a "buy" rating and set a $222.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 2nd. Royal Bank of Canada reissued an "outperform" rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Finally, UBS Group cut their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating on the stock in a research note on Friday, March 1st. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $190.92.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $1.85 during mid-day trading on Wednesday, hitting $112.68. The company had a trading volume of 604,542 shares, compared to its average volume of 939,034. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70. The stock has a market cap of $7.11 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.76 and a beta of 0.62. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The firm's 50 day simple moving average is $109.25 and its two-hundred day simple moving average is $117.39.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.